Annual CFI
$176.54 M
+$87.40 M+98.05%
31 December 2023
Summary:
Adaptimmune Therapeutics annual cash flow from investing activities is currently $176.54 million, with the most recent change of +$87.40 million (+98.05%) on 31 December 2023. During the last 3 years, it has risen by +$455.46 million (+163.29%). ADAP annual CFI is now at all-time high.ADAP Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$66.02 M
-$65.28 M-8785.33%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly cash flow from investing activities is currently -$66.02 million, with the most recent change of -$65.28 million (-8785.33%) on 30 September 2024. Over the past year, it has dropped by -$123.32 million (-215.20%). ADAP quarterly CFI is now -196.80% below its all-time high of $68.20 million, reached on 31 December 2023.ADAP Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$1.08 M
-$123.32 M-99.13%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM cash flow from investing activities is currently $1.08 million, with the most recent change of -$123.32 million (-99.13%) on 30 September 2024. Over the past year, it has dropped by -$128.22 million (-99.17%). ADAP TTM CFI is now -99.39% below its all-time high of $176.54 million, reached on 31 December 2023.ADAP TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +98.0% | -215.2% | -99.2% |
| 3 y3 years | +163.3% | -289.4% | -99.0% |
| 5 y5 years | +1111.3% | -288.4% | -94.3% |
ADAP Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +163.3% | -196.8% | at low | -99.4% | at low |
| 5 y | 5 years | at high | +163.3% | -196.8% | +64.7% | -99.4% | +100.4% |
| alltime | all time | at high | +163.3% | -196.8% | +64.7% | -99.4% | +100.4% |
Adaptimmune Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$66.02 M(+8785.3%) | $1.08 M(-99.1%) |
| June 2024 | - | -$743.00 K(+107.5%) | $124.40 M(-2.7%) |
| Mar 2024 | - | -$358.00 K(-100.5%) | $127.84 M(-27.6%) |
| Dec 2023 | $176.54 M(+98.1%) | $68.20 M(+19.0%) | $176.54 M(+36.5%) |
| Sept 2023 | - | $57.31 M(+2027.2%) | $129.29 M(+28.2%) |
| June 2023 | - | $2.69 M(-94.4%) | $100.84 M(-29.1%) |
| Mar 2023 | - | $48.34 M(+130.7%) | $142.25 M(+59.6%) |
| Dec 2022 | $89.14 M(+17.6%) | $20.95 M(-27.4%) | $89.14 M(+124.6%) |
| Sept 2022 | - | $28.85 M(-34.6%) | $39.69 M(-13.1%) |
| June 2022 | - | $44.11 M(-1023.7%) | $45.69 M(-7.2%) |
| Mar 2022 | - | -$4.78 M(-83.2%) | $49.26 M(-35.0%) |
| Dec 2021 | $75.80 M(-127.2%) | -$28.49 M(-181.8%) | $75.80 M(-32.3%) |
| Sept 2021 | - | $34.85 M(-26.9%) | $111.90 M(+126.2%) |
| June 2021 | - | $47.68 M(+119.1%) | $49.47 M(-126.7%) |
| Mar 2021 | - | $21.76 M(+186.0%) | -$185.22 M(-33.6%) |
| Dec 2020 | -$278.92 M(-393.8%) | $7.61 M(-127.6%) | -$278.92 M(+6.1%) |
| Sept 2020 | - | -$27.58 M(-85.3%) | -$262.85 M(+31.3%) |
| June 2020 | - | -$187.00 M(+159.9%) | -$200.22 M(-3848.1%) |
| Mar 2020 | - | -$71.95 M(-403.8%) | $5.34 M(-94.4%) |
| Dec 2019 | $94.94 M | $23.68 M(-32.4%) | $94.94 M(+403.7%) |
| Sept 2019 | - | $35.05 M(+88.8%) | $18.85 M(-223.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $18.56 M(+5.1%) | -$15.25 M(+13.5%) |
| Mar 2019 | - | $17.66 M(-133.7%) | -$13.44 M(-23.0%) |
| Dec 2018 | -$17.46 M(-86.2%) | -$52.41 M(-5663.8%) | -$17.46 M(+245.2%) |
| Sept 2018 | - | $942.00 K(-95.4%) | -$5.06 M(-234.8%) |
| June 2018 | - | $20.37 M(+49.4%) | $3.75 M(-104.2%) |
| Mar 2018 | - | $13.64 M(-134.1%) | -$89.81 M(-28.8%) |
| Dec 2017 | -$126.08 M(-810.1%) | -$40.01 M(-510.3%) | -$126.08 M(+82.4%) |
| Sept 2017 | - | $9.75 M(-113.3%) | -$69.11 M(-5.5%) |
| June 2017 | - | -$73.18 M(+223.3%) | -$73.12 M(-1386.9%) |
| Mar 2017 | - | -$22.64 M(-233.5%) | $5.68 M(-68.0%) |
| Dec 2016 | $17.75 M(-280.5%) | $16.96 M(+195.3%) | $17.75 M(+2130.5%) |
| Sept 2016 | - | $5.74 M(+2.2%) | $796.00 K(-105.4%) |
| June 2016 | - | $5.62 M(-153.2%) | -$14.81 M(-27.5%) |
| Mar 2016 | - | -$10.56 M(+7.1%) | -$20.43 M(-43.3%) |
| Dec 2015 | -$9.84 M(-83.3%) | - | - |
| Sept 2015 | - | -$9.86 M(-62.3%) | -$36.04 M(+35.0%) |
| June 2015 | -$58.84 M(+4207.2%) | - | - |
| Dec 2014 | - | -$26.18 M(+4859.9%) | -$26.71 M(+4959.9%) |
| Sept 2014 | - | -$527.80 K | -$527.80 K |
| June 2014 | -$1.37 M(+755.9%) | - | - |
| June 2013 | -$159.60 K | - | - |
FAQ
- What is Adaptimmune Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual CFI year-on-year change?
- What is Adaptimmune Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly CFI year-on-year change?
- What is Adaptimmune Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM CFI year-on-year change?
What is Adaptimmune Therapeutics annual cash flow from investing activities?
The current annual CFI of ADAP is $176.54 M
What is the all time high annual CFI for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual cash flow from investing activities is $176.54 M
What is Adaptimmune Therapeutics annual CFI year-on-year change?
Over the past year, ADAP annual cash flow from investing activities has changed by +$87.40 M (+98.05%)
What is Adaptimmune Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ADAP is -$66.02 M
What is the all time high quarterly CFI for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly cash flow from investing activities is $68.20 M
What is Adaptimmune Therapeutics quarterly CFI year-on-year change?
Over the past year, ADAP quarterly cash flow from investing activities has changed by -$123.32 M (-215.20%)
What is Adaptimmune Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ADAP is $1.08 M
What is the all time high TTM CFI for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM cash flow from investing activities is $176.54 M
What is Adaptimmune Therapeutics TTM CFI year-on-year change?
Over the past year, ADAP TTM cash flow from investing activities has changed by -$128.22 M (-99.17%)